Company Registry

Paganini Biopharma Inc
Profile last edited on: 4/30/2019

MAb against the target in development for triple-negative breast cancer
Year Founded
2011
First SBIR Year
2014
Latest SBIR Award
2014
Program Status
Inactive (Acquired)

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

17328 Ventura Boulevard Suite 147
Encino, CA 91316
   (818) 784-5527
   N/A
   N/A
Multiple Locations:   
Congressional District:   30
County:   Los Angeles

Public Profile

Spun out of UCLA, Paganini Biopharma, Inc. had been a development stage biotechnology company focused on therapeutics for cancer. The firm was acquired in 2017 by OncoResponses. Paganini's first product had been a unique human monoclonal antibody that targets breast cancer stem cells and was being developed for triple negative breast cancer. Paganini’s lead drug, ONCR-201 - a monoclonal antibody developed to target epithelial membrane protein 2, a protein shown in research to have a role in ovarian cancer. OncoResponse was itself only founded in 2015 - having been launched as a firm when Theraclone - a Seattle biotech company -and the University of Texas M.D. Anderson Cancer Center announced the formation of a new company seeking to find personalized antibodies that c/would help fight cancer.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
---
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
1 NIH $224,997
Targeting Breast Cancer Stem Cells with PG-101

Key People / Management

  Gary Lazar -- President and CEO